Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload.
Limited therapies exist for patients with congenital heart disease (CHD) who develop right ventricular (RV) dysfunction. Bone marrow-derived mesenchymal stem cells (MSCs) have not been evaluated in a preclinical model of pressure overload, which simulates the pathophysiology relevant to many forms of CHD. A neonatal swine model of RV pressure overload was utilized to test the hypothesis that MSCs preserve RV function and attenuate ventricular remodeling. Immunosuppressed Yorkshire swine underwent pulmonary artery banding to induce RV dysfunction. After 30 min, human MSCs (1 million cells, n = 5) or placebo (n = 5) were injected intramyocardially into the RV free wall. Serial transthoracic echocardiography monitored RV functional indices including 2D myocardial strain analysis. Four weeks postinjection, the MSC-treated myocardium had a smaller increase in RV end-diastolic area, end-systolic area, and tricuspid vena contracta width (P < 0.01), increased RV fractional area of change, and improved myocardial strain mechanics relative to placebo (P < 0.01). The MSC-treated myocardium demonstrated enhanced neovessel formation (P < 0.0001), superior recruitment of endogenous c-kit+ cardiac stem cells to the RV (P < 0.0001) and increased proliferation of cardiomyocytes (P = 0.0009) and endothelial cells (P < 0.0001). Hypertrophic changes in the RV were more pronounced in the placebo group, as evidenced by greater wall thickness by echocardiography (P = 0.008), increased cardiomyocyte cross-sectional area (P = 0.001), and increased expression of hypertrophy-related genes, including brain natriuretic peptide, β-myosin heavy chain and myosin light chain. Additionally, MSC-treated myocardium demonstrated increased expression of the antihypertrophy secreted factor, growth differentiation factor 15 (GDF15), and its downstream effector, SMAD 2/3, in cultured neonatal rat cardiomyocytes and in the porcine RV myocardium. This is the first report of the use of MSCs as a therapeutic strategy to preserve RV function and attenuate remodeling in the setting of pressure overload. Mechanistically, transplanted MSCs possibly stimulated GDF15 and its downstream SMAD proteins to antagonize the hypertrophy response of pressure overload. These encouraging results have implications in congenital cardiac pressure overload lesions.
['Wehman|Brody|B|', 'Sharma|Sudhish|S|', 'Pietris|Nicholas|N|', 'Mishra|Rachana|R|', 'Siddiqui|Osama T|OT|', 'Bigham|Grace|G|', 'Li|Tieluo|T|', 'Aiello|Emily|E|', 'Murthi|Sarah|S|', 'Pittenger|Mark|M|', 'Griffith|Bartley|B|', 'Kaushal|Sunjay|S|']
D000818:Animals D004195:Disease Models, Animal D006801:Humans D017380:Hypertrophy, Right Ventricular D045164:Mesenchymal Stem Cell Transplantation D018995:Myosin Heavy Chains D018994:Myosin Light Chains D020097:Natriuretic Peptide, Brain D013552:Swine D018497:Ventricular Dysfunction, Right D017725:Ventricular Pressure D020257:Ventricular Remodeling
pressure overload congenital heart disease right ventricle stem cell therapy